Skip to main content

Table 1 Summary of clinical and virological findings in experimental vaccine groups

From: Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination

Vaccine

group

Sheep number

Fevera (Y/N)

Fever onsetb (day)

No. days feverc

Max temp (day)d

Viremia (Y/N)e

Viremia onset (day)f

No. days viremiag

Max titer (logTCID50)h

Control

4226

Y

3

2

41.0 (3)

Y

2

3

2.9

4239

Y

2

1

40.5 (2)

Y

2

1

2.5

4243

Y

1

3

41.5 (1)

Y

2

2

4.2

4253

Y

1

2

41.1 (1&2)

Y

2

2

3.1

4255

Y

2

3

41.5 (4)

Y

2

4

5.6

DNA (3X)

1230

N

n/a

0

n/a

N

n/a

n/a

n/a

1232

Y

5

3

40.5 (6)

N

n/a

n/a

n/a

1237

Y

3

1

41.3 (3)

Y

3

2

3

1238

Y

4

3

41.7 (4)

Y

4

1

2.3

1239

Y

4

1

40.9 (4)

N

n/a

n/a

n/a

MVA (2X)

1024

Y

2

1

40.3 (2)

Y

2

2

3.6

1025

Y

1

2

41.3 (1)

Y

2

2

4.2

1563

Y

1

1

41.2 (1)

Y

2

2

4

1564

Y

1

3

40.9 (1)

Y

2

4

4.8

1139

Y

2

1

40.8 (2)

Y

2

2

4

DNA + MVA

1526

Y

2

7

41.6 (5)

Y

2

2

3.4

1527

N

n/a

0

n/a

N

n/a

n/a

n/a

1528

Y

2

1

42.0 (2)

N

n/a

n/a

n/a

1529

Y

2

5

41.3 (2)

Y

2

2

3.6

1530

Y

3

2

40.8 (3)

N

n/a

n/a

n/a

  1. aDetection of rectal temperature ≥ 40.3 °C.
  2. bDay after challenge in which fever is detected for first time.
  3. cNumber of days in which temperature ≥ 40.3 °C is detected.
  4. dMaximum temperature detected and day.
  5. eDetection of virus in blood samples.
  6. fDay post-challenge at which viremia is detected for first time.
  7. gNumber of days in which viremia is detected.
  8. hMaximum viremia titer post-challenge.